SCHEMBL10074740

SCHEMBL10074740

CCC1CC=CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13453019 1.00
SCHEMBL11895917 0.75
SCHEMBL15150018 0.74
SCHEMBL15150022 0.74
SCHEMBL3408289 0.74
SCHEMBL15547650 0.67
SCHEMBL27595625 0.67
SCHEMBL15149745 0.64
SCHEMBL12448905 0.63
SCHEMBL257210 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117088885-A Triazolopyridazine compound and application thereof 上海赛默罗生物科技有限公司 2023-11-21 CN disclosed
CN-107848967-B Cyclic quaternary ammonium salts as fuel or lubricant additives 因诺斯佩克有限公司 2022-05-27 CN disclosed
US-20120328546-A1 Paxillin Stimulating Compositions and Cosmetic Uses Thereof AVON PRODUCTS, INC. (US) 2012-12-27 US disclosed
US-8168212-B2 Topical compositions comprising non-proteogenic amino acids and methods of treating skin AVON PRODUCTS, INC (US) 2012-05-01 US disclosed
US-20110151029-A1 Paxillin Stimulating Compositions and Cosmetic Uses Thereof AVON PRODUCTS, INC. (US) 2011-06-23 US disclosed
US-20100330109-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-30 US disclosed
US-20100261769-A1 Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin AVON PRODUCTS, INC. (US) 2010-10-14 US disclosed
US-7790729-B2 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE INC. (CA) 2010-09-07 US disclosed
US-20100216766-A1 Inhibitors of VEGF Receptor and HGF Receptor Signalling 92229129 QUEBEC INC. (CA) 2010-08-26 US disclosed
US-7776887-B2 producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-08-17 US disclosed
US-20100063267-A1 BI-FUNCTIONAL COMPOUND POSITIVELY CHARGED AT FIRST PH AND NEGATIVELY CHARGED AT SECOND PH, SOLID SUPPORT COMPRISING THE BI-FUNCTIONAL COMPOUND, AND METHOD OF ISOLATING NUCLEIC ACID USING THE SAME SAMSUNG ELECTRONICS CO., LTD (KR) 2010-03-11 US disclosed
US-7378422-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-05-27 US disclosed
US-7273885-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-09-25 US disclosed
US-7241796-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INC. (US) 2007-07-10 US disclosed
US-4047964-A BENZISOXAZOLE FUJI PHOTO FILM CO., LTD. (JA) 1977-09-13 US disclosed